Cargando…
Knowledge domain and emerging trends in empagliflozin for heart failure: A bibliometric and visualized analysis
OBJECTIVE: Empagliflozin (EMPA), a sodium-glucose cotransporter 2 inhibitor (SGLT2i), is recommended for all patients with Heart failure (HF) to reduce the risk of Cardiovascular death, hospitalization, and HF exacerbation. Qualitative and quantitative evaluation was conducted by searching relevant...
Autores principales: | Zhang, Xuesong, Zhang, Ying, Hu, Yuanhui |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668858/ https://www.ncbi.nlm.nih.gov/pubmed/36407420 http://dx.doi.org/10.3389/fcvm.2022.1039348 |
Ejemplares similares
-
Cost-effectiveness of empagliflozin for the treatment of heart failure with reduced ejection fraction in China
por: Sang, Haiqiang, et al.
Publicado: (2022) -
Global research trends in atherosclerosis: A bibliometric and visualized study
por: Tian, Wende, et al.
Publicado: (2022) -
Psycho-Cardiological Disease: A Bibliometric Review From 2001 to 2021
por: You, Yaping, et al.
Publicado: (2022) -
Emerging trends and hotspots evolution in cardiotoxicity: A bibliometric and knowledge-Map analysis From 2010 to 2022
por: Xiao, Di, et al.
Publicado: (2023) -
Empagliflozin in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Pan, Deng, et al.
Publicado: (2021)